Immix Biopharma Inc
NASDAQ:IMMX

Watchlist Manager
Immix Biopharma Inc Logo
Immix Biopharma Inc
NASDAQ:IMMX
Watchlist
Price: 2.4 USD 2.13% Market Closed
Market Cap: 66.9m USD

Relative Value

There is not enough data to reliably calculate the relative value of IMMX.

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

IMMX Relative Value
Base Case
Not Available
Worst Case
Base Case
Best Case

Valuation Multiples

vs History
vs Industry
Median 3Y
0
Median 5Y
0
Industry
7.2
vs History
vs Industry
Median 3Y
-3
Median 5Y
-2.9
Industry
23.2
Forward
-2.9
vs History
vs Industry
Median 3Y
-4.3
Median 5Y
-4.3
Industry
19.3
vs History
vs Industry
Median 3Y
-4.1
Median 5Y
-4.3
Industry
22.5
vs History
2
vs Industry
32
Median 3Y
2.5
Median 5Y
2.5
Industry
2.7
vs History
vs Industry
Median 3Y
0
Median 5Y
0
Industry
7.5
vs History
vs Industry
Median 3Y
0
Median 5Y
0
Industry
9.4
vs History
vs Industry
Median 3Y
-1.9
Median 5Y
-2
Industry
4.6
Forward
-2.4
vs History
vs Industry
Median 3Y
-1.9
Median 5Y
-2
Industry
4.5
Forward
-1.9
vs History
vs Industry
Median 3Y
-2.3
Median 5Y
-2.4
Industry
4.9
vs History
vs Industry
Median 3Y
-2.3
Median 5Y
-2.3
Industry
3.7
vs History
vs Industry
15
Median 3Y
13.2
Median 5Y
13.5
Industry
4.9

Multiples Across Competitors

IMMX Competitors Multiples
Immix Biopharma Inc Competitors

Market Cap P/S P/E EV/EBITDA EV/EBIT
US
Immix Biopharma Inc
NASDAQ:IMMX
66.8m USD 0 -3.2 -2.4 -2.3
FR
Pharnext SCA
OTC:PNEXF
6T USD 34 345 565.3 -163 239.4 -198 224.7 -195 962.7
US
Abbvie Inc
NYSE:ABBV
337.1B USD 5.9 81.1 15.4 22.8
US
Amgen Inc
NASDAQ:AMGN
158.9B USD 4.7 26.8 14.4 23.7
US
Gilead Sciences Inc
NASDAQ:GILD
138B USD 4.8 23.1 10.1 13.9
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
115.9B USD 10.4 -117.2 24.9 26.1
US
Epizyme Inc
F:EPE
94.1B EUR 2 051.2 -523.4 -569.9 -554.7
AU
CSL Ltd
ASX:CSL
115.8B AUD 5 27.5 17 21.2
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
56.6B USD 4 12.6 11.2 12.5
US
Seagen Inc
F:SGT
39.3B EUR 19.8 -60.6 -65.3 -58.9
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
40.2B USD 17.1 -149 -667.3 -334.4
P/S Multiple
Revenue Growth P/S to Growth
US
Immix Biopharma Inc
NASDAQ:IMMX
Average P/S: 3 434 768.8
Not Available
N/A N/A
FR
Pharnext SCA
OTC:PNEXF
34 345 565.3
N/A N/A
US
Abbvie Inc
NYSE:ABBV
5.9
8%
0.7
US
Amgen Inc
NASDAQ:AMGN
4.7
4%
1.2
US
Gilead Sciences Inc
NASDAQ:GILD
4.8
3%
1.6
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
10.4
10%
1
US
E
Epizyme Inc
F:EPE
2 051.2
N/A N/A
AU
CSL Ltd
ASX:CSL
5
7%
0.7
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
4
4%
1
US
S
Seagen Inc
F:SGT
19.8
30%
0.7
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
17.1
29%
0.6
P/E Multiple
Earnings Growth PEG
US
Immix Biopharma Inc
NASDAQ:IMMX
Average P/E: 34.2
Negative Multiple: -3.2
N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -163 239.4 N/A N/A
US
Abbvie Inc
NYSE:ABBV
81.1
88%
0.9
US
Amgen Inc
NASDAQ:AMGN
26.8
45%
0.6
US
Gilead Sciences Inc
NASDAQ:GILD
23.1
188%
0.1
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Negative Multiple: -117.2 N/A N/A
US
E
Epizyme Inc
F:EPE
Negative Multiple: -523.4 N/A N/A
AU
CSL Ltd
ASX:CSL
27.5
16%
1.7
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
12.6
7%
1.8
US
S
Seagen Inc
F:SGT
Negative Multiple: -60.6 N/A N/A
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
Negative Multiple: -149 N/A N/A
EV/EBITDA Multiple
EBITDA Growth EV/EBITDA to Growth
US
Immix Biopharma Inc
NASDAQ:IMMX
Average EV/EBITDA: 15.5
Negative Multiple: -2.4
N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -198 224.7 N/A N/A
US
Abbvie Inc
NYSE:ABBV
15.4
13%
1.2
US
Amgen Inc
NASDAQ:AMGN
14.4
17%
0.8
US
Gilead Sciences Inc
NASDAQ:GILD
10.1
6%
1.7
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
24.9
17%
1.5
US
E
Epizyme Inc
F:EPE
Negative Multiple: -569.9 N/A N/A
AU
CSL Ltd
ASX:CSL
17
11%
1.5
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
11.2
11%
1
US
S
Seagen Inc
F:SGT
Negative Multiple: -65.3 N/A N/A
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
Negative Multiple: -667.3 N/A N/A
EV/EBIT Multiple
EBIT Growth EV/EBIT to Growth
US
Immix Biopharma Inc
NASDAQ:IMMX
Average EV/EBIT: 20
Negative Multiple: -2.3
N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -195 962.7 N/A N/A
US
Abbvie Inc
NYSE:ABBV
22.8
29%
0.8
US
Amgen Inc
NASDAQ:AMGN
23.7
32%
0.7
US
Gilead Sciences Inc
NASDAQ:GILD
13.9
11%
1.3
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
26.1
17%
1.5
US
E
Epizyme Inc
F:EPE
Negative Multiple: -554.7 N/A N/A
AU
CSL Ltd
ASX:CSL
21.2
14%
1.5
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
12.5
11%
1.1
US
S
Seagen Inc
F:SGT
Negative Multiple: -58.9 N/A N/A
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
Negative Multiple: -334.4 N/A N/A